Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis - 05/09/20
| Disclosure of potential conflict of interest: B. Lipworth reports nonfinancial support (equipment) from GlaxoSmithKline; grants, personal fees (consulting, talks, and advisory board), and other support (attending American Thoracic Society and European Respiratory Society meetings) from AstraZeneca; grants, personal fees (consulting, talks, and advisory board), and other support (attending European Respiratory Society meetings) from Teva; personal fees (consulting) from Lupin, Glenmark, Vectura, Dr Reddy, and Sandoz, in relation to the submitted work; grants, personal fees (consulting, talks, and advisory board), and other support (attending British Thoracic Society meetings) from Boehringer Ingelheim; and grants and personal fees (advisory board and talks) from Mylan and grants and personal fees (consulting) from Sanofi, outside of the submitted work. His son is presently an employee of AstraZeneca. C. R. Kuo reports personal fees (talks) from AstraZeneca; personal fees (advisory board) from Circassia; personal fees (talks) in relation to the submitted work; and other support from Chiesi (attending British Thoracic Society meetings) outside of the submitted work. |
Vol 146 - N° 3
P. 683 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

